Optimizing human α-galactosidase for treatment of Fabry disease.

MLA

Hallows, William C., et al. “Optimizing Human α-Galactosidase for Treatment of Fabry Disease.” Scientific Reports, vol. 13, no. 1, Mar. 2023, pp. 1–16. EBSCOhost, https://doi.org/10.1038/s41598-023-31777-4.

APA

Hallows, W. C., Skvorak, K., Agard, N., Kruse, N., Zhang, X., Zhu, Y., Botham, R. C., Chng, C., Shukla, C., Lao, J., Miller, M., Sero, A., Viduya, J., Ismaili, M. H. A., McCluskie, K., Schiffmann, R., Silverman, A. P., Shen, J.-S., & Huisman, G. W. (2023). Optimizing human α-galactosidase for treatment of Fabry disease. Scientific Reports, 13(1), 1–16. https://doi.org/10.1038/s41598-023-31777-4

Chicago

Hallows, William C., Kristen Skvorak, Nick Agard, Nikki Kruse, Xiyun Zhang, Yu Zhu, Rachel C. Botham, et al. 2023. “Optimizing Human α-Galactosidase for Treatment of Fabry Disease.” Scientific Reports 13 (1): 1–16. doi:10.1038/s41598-023-31777-4.